AI 기반 의료용 스케줄링 소프트웨어 시장 : 규모, 점유율과 동향 분석, 제품 유형별, 전개 모델별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

AI in Medical Scheduling Software Market Summary

The global AI in medical scheduling software market size was estimated at USD 159.79 million in 2024 and is projected to reach USD 1,451.41 million by 2033, growing at a CAGR of 28.1% from 2025 to 2033. The need for healthcare providers to improve staff allocation, reduce patient wait times, and increase operational efficiency is propelling the growth of AI in medical scheduling software markets.

Predictive analytics can be used to accurately forecast patient no-shows and appointment congestion. To provide individualized appointment organizing and effective use of clinical resources, healthcare organizations are emphasizing workflow automation and better patient experiences.

Healthcare providers use AI-driven scheduling systems to increase staffing levels and operational effectiveness. These systems minimize booking conflicts, ease administrative burdens, and use clinical resources by automating appointment assignments and assigning up workloads between doctors and support personnel. Hospital and clinic operations grow more efficiently, enhancing patient flow and provider productivity. In January 2025, the growing use of the latest innovations to boost productivity and care is demonstrated by a University of Minnesota study that found 65% of U.S. hospitals are effectively utilizing artificial intelligence assisted predictive tools for appointment management.

Healthcare organizations use predictive analytics to forecast patient cancellations, no-shows, and appointment congestion. Artificial intelligence algorithms analyze past data and behavior patterns to identify potential appointment disruptions and prepare proactively. This capability reduces idle time, improves appointment adherence, and ensures more accurate planning of clinical services. In November 2023, Health Policy and Technology published a metanarrative review of AI in patient appointments, demonstrating that implementations vary, and it can optimize appointments, lessen provider workload, and increase satisfaction.

AI software reduces administrative workload and manual labor by automating processes. Improved satisfaction is a result of real-time updates, effective departmental coordination, and customized arrangements. Healthcare facilities benefit from improved operational control and service quality, while its users benefit from shorter wait times, prompt reminders, and flexible appointment completions. In March 2024, Bioengineering highlighted AI's role in hospital operations, specifically showing how software optimizes staff allocation, appointments, and workflow efficiency, reducing bottlenecks and improving resource utilization.

Global AI in Medical Scheduling Software Market Report Segmentation

This report forecasts, revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented global AI in medical scheduling software market report based on product type, deployment model, end use, and region.

• Product Type Outlook (Revenue, USD Million, 2021 - 2033)
• Patient Scheduling
• Nurse Scheduling
• Care Provider Scheduling
• Others
• Deployment Model Outlook (Revenue, USD Million, 2021 - 2033)
• Cloud-based
• On-Premises
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Clinics
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Type Segment
  • 1.2.2. Deployment Model Segment
  • 1.2.3. End Use
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. AI in Medical Scheduling Software Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing need for efficient patient scheduling and workflow optimization
    • 3.2.1.2. Advancements in AI technologies
    • 3.2.1.3. Supportive government policies and healthcare digitization initiatives
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Data privacy and security concerns
    • 3.2.2.2. High implementation and maintenance costs
  • 3.2.3. Market opportunity analysis
  • 3.2.4. Market challenges analysis
• 3.3. AI in Medical Scheduling Software Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
    • 3.3.2.4. Environmental Landscape
    • 3.3.2.5. Legal Landscape
    • 3.3.2.6. Social Landscape
• 3.4. Case Study Insights
• 3.5. Technology Analysis: Key Use Cases and Application
  • 3.5.1. Machine Learning (ML)/Deep Learning
  • 3.5.2. Natural Language Processing (NLP)
  • 3.5.3. Computer Vision-based Image Analysis

Chapter 4. AI in Medical Scheduling Software Market: Product Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global AI in Medical Scheduling Software Market Product Type Movement Analysis
• 4.3. Global AI in Medical Scheduling Software Market Size & Trend Analysis, by Product Type, 2021 to 2033 (USD Million)
• 4.4. Patient Scheduling
  • 4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.5. Nurse Scheduling
  • 4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.6. Care Provider Scheduling
  • 4.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.7. Others
  • 4.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. AI in Medical Scheduling Software Market: Deployment Model Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global AI in Medical Scheduling Software Market Deployment Model Movement Analysis
• 5.3. Global AI in Medical Scheduling Software Market Size & Trend Analysis, by Deployment Model, 2021 to 2033 (USD Million)
• 5.4. Cloud-based
  • 5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.5. On-Premises
  • 5.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. AI in Medical Scheduling Software Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global AI in Medical Scheduling Software Market End Use Movement Analysis
• 6.3. Global AI in Medical Scheduling Software Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.5. Clinics
  • 6.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. AI in Medical Scheduling Software Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.4.3. Mexico
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.2. Germany
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.3. France
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.4. Italy
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.5. Spain
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.6. Norway
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Regulatory framework
    • 7.5.8.3. Competitive scenario
    • 7.5.8.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6.3. India
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6.4. Australia
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6.6. Thailand
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.7.2. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.8.3. UAE
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.8.4. Kuwait
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Regulatory framework
    • 7.8.4.3. Competitive scenario
    • 7.8.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Notable
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Hyro
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Voiceoc
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Veradigm LLC
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Proscia Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Analog Informatics Corporation
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. ScienceSoft USA Corporation
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Epic Systems Corporation
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. CCD HEALTH A GEBBS HEALTHCARE COMPANY
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Zocdoc
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. Qualifacts
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives
  • 8.4.12. eClinicalWorks
    • 8.4.12.1. Company overview
    • 8.4.12.2. Financial performance
    • 8.4.12.3. Product benchmarking
    • 8.4.12.4. Strategic initiatives